BioCentury
ARTICLE | Clinical News

MVA-BN Filo: Phase III started

October 19, 2015 7:00 AM UTC

Johnson & Johnson began the open-label, Sierra Leonean Phase III EBOVAC-Salone trial to evaluate 0.5 mL intramuscular Ad26.ZEBOV followed by 0.5 mL intramuscular MVA-BN Filo 2 months later in about 440 healthy volunteers. The first part of the study will enroll about 40 adults; the second part will enroll about 400 subjects ages >=1. ...